| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103452 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(16 years from now) | |
| US11752103 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(16 years from now) | |
Qdolo is owned by Athena.
Qdolo contains Tramadol Hydrochloride.
Qdolo has a total of 2 drug patents out of which 0 drug patents have expired.
Qdolo was authorised for market use on 01 September, 2020.
Qdolo is available in solution;oral dosage forms.
Qdolo can be used as management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The generics of Qdolo are possible to be released after 01 September, 2040.
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION;ORAL
QDOLO family patents
